title: Clinical buffering of metabolic acidosis: problems and a solution.
abstract: Traditionally sodium bicarbonate has been the buffer of first choice in the treatment of metabolic acidosis. This treatment, however, involves risks of developing a hyperosmolar state, a high sodium concentration in the blood, increased arterial carbon dioxide tension and, as a result of the latter, intracellular and intracerebral acidosis and also cerebral oedema. The buffering effect occurs slowly and as a consequence of this, and of the titration curve of sodium bicarbonate, overcorrection of metabolic acidosis is often seen. Tris buffer was introduced as an alternative and has been claimed to solve most of these problems, but on the other hand it entails a very high risk of peripheral venous thrombosis and thrombophlebitic lesions owing to its local irritative effect. In order to overcome these disadvantages a new mixture of Tris, acetate, bicarbonate and phosphate has been designed. In the studies described it was shown to have an adequate buffering effect and to provide a solution to most of the problems connected with buffering of metabolic acidosis. The new Tris buffer mixture has a buffering effect in blood equivalent to 0.5 mol/l sodium bicarbonate, although its sodium content has been decreased to one-third of pure sodium bicarbonate. Its administration also results in predictable buffering in cerebrospinal fluid and skeletal muscle. In a clinical study it was demonstrated that the new Tris buffer mixture results in sufficient and adequate buffering without significant side-effects.
authors.forename: L
authors.initials: L
authors.lastname: Wiklund
authors.forename: L
authors.initials: L
authors.lastname: Oquist
authors.forename: G
authors.initials: G
authors.lastname: Skoog
authors.forename: H
authors.initials: H
authors.lastname: Tydén
authors.forename: L
authors.initials: L
authors.lastname: Jorfeldt
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000138:Acidosis / Q000188:drug therapy*; D000818:Animals; D001639:Bicarbonates / Q000009:adverse effects / Q000627:therapeutic use; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D051379:Mice; D009994:Osmolar Concentration; D010710:Phosphates / Q000627:therapeutic use; D012306:Risk; D012964:Sodium / Q000009:adverse effects / Q000627:therapeutic use; D017693:Sodium Bicarbonate; D013552:Swine; D013997:Time Factors; D014325:Tromethamine / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D000085:Acetates; D001639:Bicarbonates; D010710:Phosphates; D014325:Tromethamine; D002245:Carbon Dioxide; D017693:Sodium Bicarbonate; D012964:Sodium